TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...

Basel: Roche announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO ...

Roche announced that the United States Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and ...

Subcutaneous ocrelizumab and hyaluronidase (Ocrevus Zunovo) was approved for relapsing and progressive multiple sclerosis, ...

In collaboration with Roche (LON:0QQ6), Halozyme has secured U.S. approval for Ocrevus Zunovo, a subcutaneous version of Ocrevus for multiple sclerosis. The approval of Ocrevus Zunovo, which offers a ...

In collaboration with Roche, Halozyme has secured U.S. approval for Ocrevus Zunovo, a subcutaneous version of Ocrevus for multiple sclerosis. The approval of Ocrevus Zunovo, which offers a ...

In collaboration with Roche, Halozyme has gained U.S. approval for Ocrevus Zunovo, a new multiple sclerosis treatment, and Tecentriq Hybreza, a subcutaneous form of Tecentriq. These treatments ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Roche received U.S. Food and Drug Administration (FDA) approval for OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) with ...